Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to -$427930.0.

  • Onconetix's Change in Accured Expenses fell 13833.07% to -$427930.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$494151.0, marking a year-over-year increase of 5239.32%. This contributed to the annual value of -$1.1 million for FY2024, which is 1984.71% down from last year.
  • As of Q3 2025, Onconetix's Change in Accured Expenses stood at -$427930.0, which was down 13833.07% from -$279731.0 recorded in Q2 2025.
  • In the past 5 years, Onconetix's Change in Accured Expenses ranged from a high of $269779.0 in Q1 2025 and a low of -$775008.0 during Q2 2023
  • In the last 3 years, Onconetix's Change in Accured Expenses had a median value of -$214311.0 in 2023 and averaged -$228091.5.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 154242.45% in 2024, then skyrocketed by 20324.37% in 2025.
  • Over the past 3 years, Onconetix's Change in Accured Expenses (Quarter) stood at $34796.0 in 2023, then plummeted by 261.71% to -$56269.0 in 2024, then plummeted by 660.51% to -$427930.0 in 2025.
  • Its Change in Accured Expenses was -$427930.0 in Q3 2025, compared to -$279731.0 in Q2 2025 and $269779.0 in Q1 2025.